MA43106B1 - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number: MA43106B1
Authority: MA; Morocco
Prior art keywords: oligo; treatment; hepatic steatosis; ovulation; composition
Prior art date: 2015-10-27

Application number

MA43106A

Other languages

English (en)

French (fr)

Other versions

MA43106A (fr

Inventor

Lourdes Ibáñez

Zegher Francis De

Original Assignee

Univ Leuven Kath

Sant Joan De Deu Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-27

Filing date

2016-10-27

Publication date

2021-09-30

2016-10-27 Application filed by Univ Leuven Kath, Sant Joan De Deu Hospital filed Critical Univ Leuven Kath

2021-05-05 Publication of MA43106A publication Critical patent/MA43106A/fr

2021-09-30 Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Links

206010002659 Anovulatory cycle Diseases 0.000 title 1
206010019708 Hepatic steatosis Diseases 0.000 title 1
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
230000002440 hepatic effect Effects 0.000 abstract 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
229960003105 metformin Drugs 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
229960002256 spironolactone Drugs 0.000 abstract 1
230000009278 visceral effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1518979.8A GB201518979D0 (en)	2015-10-27	2015-10-27	Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (en)	2015-10-27	2016-10-27	Treatment of hepatic steatosis related oligo-ovulation

Publications (2)

Publication Number	Publication Date
MA43106A MA43106A (fr)	2021-05-05
MA43106B1 true MA43106B1 (fr)	2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA43106A MA43106B1 (fr)	2015-10-27	2016-10-27	Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA054412A MA54412A (fr)	2015-10-27	2016-10-27	Traitement d'excès de graisse hépatique et/ou viscérale

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA054412A MA54412A (fr)	2015-10-27	2016-10-27	Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country	Link
US (2)	US20190060328A1 (ko)
EP (2)	EP3368044B1 (ko)
JP (2)	JP6999903B2 (ko)
KR (1)	KR102608158B1 (ko)
CN (2)	CN108778285A (ko)
AR (1)	AR106505A1 (ko)
AU (1)	AU2016344737C1 (ko)
BR (1)	BR112018008496A2 (ko)
CA (1)	CA3003076C (ko)
DK (1)	DK3368044T3 (ko)
ES (1)	ES2883282T3 (ko)
GB (1)	GB201518979D0 (ko)
HU (1)	HUE055778T2 (ko)
IL (1)	IL258876B (ko)
LT (1)	LT3368044T (ko)
MA (2)	MA43106B1 (ko)
MX (2)	MX384040B (ko)
PL (1)	PL3368044T3 (ko)
RS (1)	RS62764B1 (ko)
RU (1)	RU2745606C2 (ko)
SI (1)	SI3368044T1 (ko)
TW (1)	TWI791420B (ko)
UY (1)	UY36967A (ko)
WO (1)	WO2017072243A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112020012336A2 (pt)	2017-12-19	2021-03-30	Akouos, Inc.	Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
JP2021533109A (ja) *	2018-08-02	2021-12-02	オスピタルサンジュアンダデウ	多嚢胞性卵巣症候群の治療に有用な医薬品有効成分の三重組合せの即時放出製剤
EP3842803A1 (en) *	2019-12-23	2021-06-30	Katholieke Universiteit Leuven	Cxcl14 in polycystic ovary syndrome
AR122078A1 (es)	2020-05-13	2022-08-10	Akouos Inc	Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4
IL303317A (en)	2020-12-01	2023-07-01	Akouos Inc	ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
KR20230127263A (ko)	2020-12-29	2023-08-31	아카우오스, 인크.	Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법
EP4473011A1 (en)	2022-02-02	2024-12-11	Akouos, Inc.	Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6046222A (en) *	1993-09-15	2000-04-04	Warner-Lambert Company	Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) *	1993-09-15	2001-03-13	Sankyo Co	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) *	2000-02-23	2006-06-15	Orentreich Foundation For The Advancement Of Science, Inc.	Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) *	2001-03-16	2001-05-09	Leuven K U Res & Dev	Growth hormone treatment
GB0108863D0 (en) *	2001-04-10	2001-05-30	Leuven K U Res & Dev	Combinational therapy
US7105489B2 (en) *	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
AU2003256988A1 (en) *	2002-12-11	2004-06-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) *	2007-02-12	2007-03-21	Leuven K U Res & Dev	Treatment for excessive adiposity
US10474539B1 (en) *	2015-12-18	2019-11-12	EMC IP Holding Company LLC	Browsing federated backups
JP2021533109A (ja) *	2018-08-02	2021-12-02	オスピタルサンジュアンダデウ	多嚢胞性卵巣症候群の治療に有用な医薬品有効成分の三重組合せの即時放出製剤

2015
- 2015-10-27 GB GBGB1518979.8A patent/GB201518979D0/en not_active Ceased
2016
- 2016-10-27 PL PL16788501T patent/PL3368044T3/pl unknown
- 2016-10-27 RU RU2018119146A patent/RU2745606C2/ru active
- 2016-10-27 HU HUE16788501A patent/HUE055778T2/hu unknown
- 2016-10-27 TW TW105134878A patent/TWI791420B/zh active
- 2016-10-27 US US15/771,317 patent/US20190060328A1/en not_active Abandoned
- 2016-10-27 CA CA3003076A patent/CA3003076C/en active Active
- 2016-10-27 MX MX2018005252A patent/MX384040B/es unknown
- 2016-10-27 AU AU2016344737A patent/AU2016344737C1/en active Active
- 2016-10-27 UY UY0001036967A patent/UY36967A/es unknown
- 2016-10-27 JP JP2018521981A patent/JP6999903B2/ja active Active
- 2016-10-27 RS RS20211116A patent/RS62764B1/sr unknown
- 2016-10-27 CN CN201680076653.5A patent/CN108778285A/zh active Pending
- 2016-10-27 LT LTEPPCT/EP2016/075953T patent/LT3368044T/lt unknown
- 2016-10-27 SI SI201631327T patent/SI3368044T1/sl unknown
- 2016-10-27 CN CN202311150878.9A patent/CN117379440A/zh active Pending
- 2016-10-27 MA MA43106A patent/MA43106B1/fr unknown
- 2016-10-27 ES ES16788501T patent/ES2883282T3/es active Active
- 2016-10-27 MA MA054412A patent/MA54412A/fr unknown
- 2016-10-27 KR KR1020187014890A patent/KR102608158B1/ko active Active
- 2016-10-27 BR BR112018008496A patent/BR112018008496A2/pt not_active Application Discontinuation
- 2016-10-27 AR ARP160103272A patent/AR106505A1/es unknown
- 2016-10-27 WO PCT/EP2016/075953 patent/WO2017072243A1/en not_active Ceased
- 2016-10-27 EP EP16788501.1A patent/EP3368044B1/en active Active
- 2016-10-27 EP EP21165556.8A patent/EP3892281A3/en not_active Withdrawn
- 2016-10-27 DK DK16788501.1T patent/DK3368044T3/da active
2018
- 2018-04-23 IL IL258876A patent/IL258876B/en unknown
- 2018-04-26 MX MX2021007976A patent/MX2021007976A/es unknown
2021
- 2021-10-21 JP JP2021172610A patent/JP2022009374A/ja active Pending
2023
- 2023-06-28 US US18/343,553 patent/US20240000804A1/en active Pending

Also Published As

Publication number	Publication date
MX384040B (es)	2025-03-14
ES2883282T3 (es)	2021-12-07
HUE055778T2 (hu)	2021-12-28
JP2022009374A (ja)	2022-01-14
SI3368044T1 (sl)	2022-05-31
UY36967A (es)	2017-05-31
IL258876B (en)	2022-03-01
EP3368044B1 (en)	2021-06-09
JP6999903B2 (ja)	2022-02-04
US20240000804A1 (en)	2024-01-04
BR112018008496A2 (pt)	2018-10-23
TW201720432A (zh)	2017-06-16
WO2017072243A9 (en)	2018-07-26
EP3368044A1 (en)	2018-09-05
AR106505A1 (es)	2018-01-24
CN108778285A (zh)	2018-11-09
CA3003076A1 (en)	2017-05-04
AU2016344737A9 (en)	2018-08-09
RU2018119146A (ru)	2019-11-28
MA54412A (fr)	2021-11-10
AU2016344737A1 (en)	2018-05-17
KR20180098234A (ko)	2018-09-03
MA43106A (fr)	2021-05-05
CN117379440A (zh)	2024-01-12
US20190060328A1 (en)	2019-02-28
CA3003076C (en)	2023-12-05
DK3368044T3 (da)	2021-09-13
TWI791420B (zh)	2023-02-11
KR102608158B1 (ko)	2023-11-29
GB201518979D0 (en)	2015-12-09
AU2016344737C1 (en)	2021-10-07
AU2016344737B2 (en)	2021-07-08
IL258876A (en)	2018-06-28
LT3368044T (lt)	2021-10-25
MX2021007976A (es)	2021-08-16
WO2017072243A8 (en)	2018-03-22
PL3368044T3 (pl)	2021-12-20
RU2745606C2 (ru)	2021-03-29
EP3892281A2 (en)	2021-10-13
JP2019501113A (ja)	2019-01-17
RU2018119146A3 (ko)	2020-02-25
WO2017072243A1 (en)	2017-05-04
MX2018005252A (es)	2018-09-18
RS62764B1 (sr)	2022-01-31
EP3892281A3 (en)	2021-11-10

Publication	Publication Date	Title
MA45819A (fr)	2018-08-15	Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
MA43335A (fr)	2018-06-06	Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MA42439A (fr)	2018-05-23	Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA41013A (fr)	2017-08-30	Compositions comprenant des souches bactériennes
MA46836A (fr)	2019-09-25	Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MD3313423T2 (ro)	2019-10-31	Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale
PH12019550076A1 (en)	2020-01-20	SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
MA49760B1 (fr)	2025-11-28	Mavacamten pour l'utilisation dans le traitement de la cardiomyopathie hypertrophique
MX2022015248A (es)	2023-01-11	Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX395317B (es)	2025-03-25	Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
PT3597816T (pt)	2021-07-05	Composições de banho de imersão para o tratamento de insertos de reforço
MD4685B1 (ro)	2020-03-31	Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2
MX2021007976A (es)	2021-08-16	Una composicion farmaceutica para usarse en el tratamiento de exceso de grasa hepatica y/o visceral.
EA036102B9 (ru)	2020-12-30	Терапевтические средства с углевод-опосредованной адресной доставкой
MA53329A (fr)	2022-03-02	Méthodes de traitement de l'épilepsie
TN2017000534A1 (en)	2019-04-12	Antibodies that bind to sortilin and inhibit the binding of progranulin
MA46459B1 (fr)	2021-03-31	Méthode de traitement de lésions rénales aiguës
EP3302474A4 (en)	2019-06-26	COMPOSITIONS FOR THE TREATMENT OF ATROPHIC VAGINITIS, PERI- AND POSTMENOPAUSAL DYSPAREUNIA AND / OR OOPHORECTORATED WOMEN AND TREATMENT METHODS THEREWITH
MX2017012610A (es)	2018-03-16	Composiciones y metodos para inhibir la expresion del gen lect2.
EP3344071A4 (en)	2019-10-16	COMBINED COMPOSITIONS FOR CONTROLLING BLOOD SUGAR MIRRORS, LIVER PROTECTION AND PREVENTING AND TREATING RELATED MEDICAL CONDITIONS
EP3632430A4 (en)	2020-06-10	AGENTS FOR THE PREVENTION OR TREATMENT OF SPINOCERBELLARY ATAXIA
MA43848A (fr)	2018-11-21	Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MX2017004842A (es)	2017-06-22	Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).
EP3429567A4 (en)	2019-12-11	METHOD AND COMPOSITIONS FOR TREATING OBESITY AND / OR DIABETES AND IDENTIFYING TREATMENT CANDIDATES
FR3032616B1 (fr)	2017-02-24	Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites